Original Publication Date: 1 November, 2015
Publication / Source: CNS Oncology
Authors: Prakash Ambady, Matthias Holdhoff, David Bonekamp, Fay Wong & Stuart A Grossman
Treatment of patients with newly diagnosed primary CNS lymphomas using high dose methotrexate regimens is reported to yield about 30% long term survivors with minimal neurotoxicity. As in other systemic large cell lymphomas, it is generally assumed that most relapses occur within 5 years of diagnosis. A retrospective review of the Johns Hopkins experience in 52 patients treated between 1995 and 2008 yielded 19 patients (37%) who achieved a complete response and were followed for over 5 years. Four of these patients remained progression-free for over 10 years.